share_log

TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260M

Benzinga ·  May 1 19:10
TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment